Having trouble accessing articles? Reset your cache.

Homology responds to reproducibility concerns

Homology is pushing back against a USC preprint study calling the reproducibility of the company’s cut-free gene editing platform into question. The study, which the company says stands in contrast to years of data supporting the technology, prompted investors to drive down the stock 20% on Thursday.

The new study, published Sunday on

Read the full 527 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers